{"filing":{"accession_number":"0001841387-26-000009","cik":"0001841387","ticker":"CADL","company_name":"Candel Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-24","report_date":null,"primary_document":"cadl-20260623.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1841387/000184138726000009/cadl-20260623.htm"},"events":[{"id":13528,"run_id":12022,"accession_number":"0001841387-26-000009","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This 8-K Item 5.07 discloses the results of Candel Therapeutics' Annual Meeting of Stockholders held on June 23, 2026. The filing reports voting outcomes for two proposals: (i) election of four Class II directors (Edward J. Benz, Jr., M.D., Paul B. Manning, Maha Radhakrishnan, M.D., and Paul Peter Tak, M.D., Ph.D., FMedSci), all of whom were elected, and (ii) ratification of KPMG LLP as independent auditor, which was ratified. The detailed vote tallies for each director and the auditor ratification are provided, making this a clear shareholder vote results disclosure material to investors' understanding of board composition and audit oversight.","company_name":"Candel Therapeutics, Inc.","ticker":"CADL","filing_date":"2026-06-24","form":"8-K","submitted_at":null,"items":[{"id":10688,"accession_number":"0001841387-26-000009","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This 8-K Item 5.07 discloses the results of Candel Therapeutics' Annual Meeting of Stockholders held on June 23, 2026. The filing reports voting outcomes for two proposals: (i) election of four Class II directors (Edward J. Benz, Jr., M.D., Paul B. Manning, Maha Radhakrishnan, M.D., and Paul Peter Tak, M.D., Ph.D., FMedSci), all of whom were elected, and (ii) ratification of KPMG LLP as independent auditor, which was ratified. The detailed vote tallies for each director and the auditor ratification are provided, making this a clear shareholder vote results disclosure material to investors' understanding of board composition and audit oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T20:25:45.462556+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10688,"accession_number":"0001841387-26-000009","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This 8-K Item 5.07 discloses the results of Candel Therapeutics' Annual Meeting of Stockholders held on June 23, 2026. The filing reports voting outcomes for two proposals: (i) election of four Class II directors (Edward J. Benz, Jr., M.D., Paul B. Manning, Maha Radhakrishnan, M.D., and Paul Peter Tak, M.D., Ph.D., FMedSci), all of whom were elected, and (ii) ratification of KPMG LLP as independent auditor, which was ratified. The detailed vote tallies for each director and the auditor ratification are provided, making this a clear shareholder vote results disclosure material to investors' understanding of board composition and audit oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T20:25:45.462556+00:00","company_name":"Candel Therapeutics, Inc.","ticker":"CADL","filing_date":"2026-06-24"}]}